Trial Profile
Multicenter Randomized Phase III Trial to Compare 6 FAC Cycles vs 4 FAC Cycles Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Negative Operable Breast Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Doxorubicin; Fluorouracil
- Indications Ductal carcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 30 May 2014 Biomarker results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 03 Jun 2013 Primary endpoint 'Disease-free-survival-rate' has been met.
- 03 Jun 2013 Results published in the Journal of Clinical Oncology.